This nanomedicine is used in the treatment of ovarian cancer, breastcancer, multiple myeloma, and Kaposi sarcoma associated with AIDS; and it isalso in clinical trial phase for some other cancers.
1. The polyethylene glycol coating (stealth polymer) reduces the uptake of liposomes by RES cells, therefore increasing the life span of liposome in the blood (half-life about 53 hours).
2. The particle diameter of approximately 100 nm enables the nanoparticles to target the tumor tissues by enhanced permeation and retention mechanism.
3. The lipid matrix with high phase transition temperature and low permeability provides stable encapsulation of the doxorubicin in nanoliposomes and the internal aqueous buffer phase provides high loading efficiency for the Doxorubicin.
Doxorubicin HCl is a drug used in cancer chemotherapy. Doxorubicin is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas. Doxorubicin's most serious adverse effect is life-threatening heart damage, which limits its application. Therefore, various efforts have been made to reduce its side effects, including encapsulating it in nanoparticle systems such as nanoliposomes. The nano-liposomal form of doxorubicin HCl (Caelyx® / Doxil®) which has been produced exclusively by a few foreign companies has entered the global market during the past few years by the approval of FDA.This product has been manufactured in Iran under the trademark of SinaDoxosome®. The formulation and physicochemical properties of SinaDoxosome® is exactly equivalent to the foreign-made product.This nanomedicine is used in the treatment of ovarian cancer, breast cancer, multiple myeloma, and Kaposi sarcoma associated with AIDS; and it is also in clinical trial phase for some other cancers.